MABF96
Anti-TRAcP Antibody, clone 9C5
clone 9C5, from mouse
Synonyme(s) :
Tartrate-resistant acid phosphatase type 5, TR-AP, Tartrate-resistant acid ATPase, TrATPase, Type 5 acid phosphatase
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Code UNSPSC :
12352203
eCl@ss :
32160702
Nomenclature NACRES :
NA.41
Produits recommandés
Source biologique
mouse
Niveau de qualité
Forme d'anticorps
purified antibody
Type de produit anticorps
primary antibodies
Clone
9C5, monoclonal
Espèces réactives
human
Technique(s)
ELISA: suitable
dot blot: suitable
immunocytochemistry: suitable
immunohistochemistry: suitable
immunoprecipitation (IP): suitable
western blot: suitable
Isotype
IgG2bκ
Numéro d'accès NCBI
Numéro d'accès UniProt
Conditions d'expédition
wet ice
Modification post-traductionnelle de la cible
unmodified
Informations sur le gène
human ... ACP5(54)
Description générale
Tartrate-resistant acid phosphatase type 5 (TRAcP), also referred to as Acp5, is secreted by osteoclasts during bone resorption. Release of TRAcP was stimulated by resorbogenic cytokines and repressed by calcitonin (a resorption inhibitor). TRAcP is also known to be expressed in high quantities in active macrophages and dendritic cells and play an essential part in presenting antigens to T cells. Inactive TRAcP released from adipose tissue macrophages has been shown to bring on hyperplastic obesity, keeping lipid metabolism and insulin sensitivity normal.
Immunogène
Full length purified protein corresponding to human TRAcP.
Application
Anti-TRAcP Antibody, clone 9C5 detects level of TRAcP & has been published & validated for use in IH, IP, DB, ELISA, IC & WB.
Research Category
Inflammation & Immunology
Inflammation & Immunology
Research Sub Category
Inflammation & Autoimmune Mechanisms
Inflammation & Autoimmune Mechanisms
Western Blot Analysis: A representative lot was used by an independent laboratory in WB. (Janckila, A.J., et al. (1995). Blood. 85:2839-2844.)
Immunoprecipitation Analysis: A representative lot was used by an independent laboratory in IP. (Janckila, A.J., et al. (1995). Blood. 85:2839-2844.)
Dot Blot Analysis: A representative lot was used by an independent laboratory in DB. (Janckila, A.J., et al. (1995). Blood. 85:2839-2844.)
ELISA Analysis: A representative lot was used by an independent laboratory in ELISA. (Janckila, A.J., et al. (1995). Blood. 85:2839-2844.)
Immunocytochemistry Analysis: A representative lot was used by an independent laboratory in IC. (Janckila, A.J., et al. (1996). The Journal of Histochemistry and Cytochemistry. 44(3):233-244.)
Immunoprecipitation Analysis: A representative lot was used by an independent laboratory in IP. (Janckila, A.J., et al. (1995). Blood. 85:2839-2844.)
Dot Blot Analysis: A representative lot was used by an independent laboratory in DB. (Janckila, A.J., et al. (1995). Blood. 85:2839-2844.)
ELISA Analysis: A representative lot was used by an independent laboratory in ELISA. (Janckila, A.J., et al. (1995). Blood. 85:2839-2844.)
Immunocytochemistry Analysis: A representative lot was used by an independent laboratory in IC. (Janckila, A.J., et al. (1996). The Journal of Histochemistry and Cytochemistry. 44(3):233-244.)
Qualité
Evaluated by Immunohistochemistry in large malignant B-cells in hairy cell leukemia tissue.
Immunohistochemistry Analysis: 1:500 dilution of this antibody detected TRAcP in large malignant B-cells in hairy cell leukemia tissue.
Immunohistochemistry Analysis: 1:500 dilution of this antibody detected TRAcP in large malignant B-cells in hairy cell leukemia tissue.
Description de la cible
36 kDa calculated
Forme physique
Format: Purified
Protein G
Purified mouse monoclonal IgG2bκ in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.
Stockage et stabilité
Stable for 1 year at 2-8°C from date of receipt.
Remarque sur l'analyse
Control
Large malignant B-cells in hairy cell leukemia tissue
Large malignant B-cells in hairy cell leukemia tissue
Autres remarques
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Clause de non-responsabilité
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Vous ne trouvez pas le bon produit ?
Essayez notre Outil de sélection de produits.
Code de la classe de stockage
12 - Non Combustible Liquids
Classe de danger pour l'eau (WGK)
WGK 1
Point d'éclair (°F)
Not applicable
Point d'éclair (°C)
Not applicable
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Christina Møller Andreasen et al.
Bone, 173, 116787-116787 (2023-05-08)
Although failure to establish a vascular network has been associated with many skeletal disorders, little is known about what drives development of vasculature in the intracortical bone compartments. Here, we show that intracortical bone resorption events are coordinated with development
Xenia G Borggaard et al.
Frontiers in molecular biosciences, 9, 896841-896841 (2022-07-02)
The strictly regulated bone remodeling process ensures that osteoblastic bone formation is coupled to osteoclastic bone resorption. This coupling is regulated by a panel of coupling factors, including clastokines promoting the recruitment, expansion, and differentiation of osteoprogenitor cells within the
Nicolai Ernlund Lassen et al.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 32(7), 1395-1405 (2017-02-09)
It is well known that bone remodeling starts with a resorption event and ends with bone formation. However, what happens in between and how resorption and formation are coupled remains mostly unknown. Remodeling is achieved by so-called basic multicellular units
Annika Nordstrand et al.
Clinical & experimental metastasis, 34(3-4), 261-271 (2017-04-28)
Prostate cancer (PCa) patients with bone metastases are primarily treated with androgen deprivation therapy (ADT). Less pronounced ADT effects are seen in metastases than in primary tumors. To test if acute effects of ADT was enhanced by concurrent inhibition of
Julia Brun et al.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 35(12), 2458-2469 (2020-08-11)
The physiological functions of platelet-derived growth factor receptors (PDGFRs) α and β in osteoblast biology and bone metabolism remain to be established. Here, we show that PDGFRA and PDGFRB genes are expressed by osteoblast-lineage canopy and reversal cells in close
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique